Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Pediatric Emergency Care|May 3, 2022
Identification of Initial and Subsequent Injury in Young Infants: Opportunities for Quality Improvement in the Evaluation of Child AbuseJonathan D Thackeray, Kristin G Crichton, Paul McPherson, et al.
Haematologica|September 17, 2016
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisVikas Gupta, Ruben A Mesa, Michael W N Deininger, et al.
Genesis (New York, N.Y. : 2000)|April 10, 2007
Drosophila Bcl-2 proteins participate in stress-induced apoptosis, but are not required for normal developmentEvgueni A Sevrioukov, John Burr, Eric W Huang, et al.
BMJ Open|May 10, 2023
Multicomponent provider-patient intervention to improve glycaemic control in Medicaid-insured pregnant individuals with type 2 diabetes: clinical trial protocol for the ACHIEVE studyKartik K Venkatesh, Joshua J Joseph, Christine Swoboda, et al.
Plos One|March 9, 2023
Addressing non-medical health-related social needs through a community-based lifestyle intervention during the COVID-19 pandemic: The Black Impact programJoshua J Joseph, Darrell M Gray, Amaris Williams, et al.
Contemporary Clinical Trials|March 12, 2026
Promoting sustained behavior change and nutrition security in medicaid-enrolled individuals with stage 2 cardiovascular kidney metabolic syndrome (CKMS): Protocol of the SUSTAIN studyDaniel M Walker, Colleen Spees, Guy Brock, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Pageof 4